HK1010447A1 - Tramadol salt containing medicaments with sustained release of the active ingredient - Google Patents

Tramadol salt containing medicaments with sustained release of the active ingredient Download PDF

Info

Publication number
HK1010447A1
HK1010447A1 HK98111000A HK98111000A HK1010447A1 HK 1010447 A1 HK1010447 A1 HK 1010447A1 HK 98111000 A HK98111000 A HK 98111000A HK 98111000 A HK98111000 A HK 98111000A HK 1010447 A1 HK1010447 A1 HK 1010447A1
Authority
HK
Hong Kong
Prior art keywords
release
weight
celluloses
pharmaceutically acceptable
active ingredient
Prior art date
Application number
HK98111000A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1010447B (en
Inventor
Antonius Bartholomaus Johannes Heinrich
Original Assignee
Grunenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6496771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1010447(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grunenthal Gmbh filed Critical Grunenthal Gmbh
Publication of HK1010447B publication Critical patent/HK1010447B/xx
Publication of HK1010447A1 publication Critical patent/HK1010447A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK98111000A 1993-09-03 1998-09-28 Tramadol salt containing medicaments with sustained release of the active ingredient HK1010447A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4329794 1993-09-03
DE4329794A DE4329794C2 (de) 1993-09-03 1993-09-03 Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung

Publications (2)

Publication Number Publication Date
HK1010447B HK1010447B (en) 1999-06-17
HK1010447A1 true HK1010447A1 (en) 1999-06-17

Family

ID=6496771

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98111000A HK1010447A1 (en) 1993-09-03 1998-09-28 Tramadol salt containing medicaments with sustained release of the active ingredient

Country Status (28)

Country Link
US (1) US5601842A (cs)
EP (1) EP0642788B1 (cs)
JP (1) JP3954117B2 (cs)
KR (1) KR100325494B1 (cs)
CN (1) CN1092956C (cs)
AT (1) ATE166575T1 (cs)
AU (1) AU671384B2 (cs)
BR (1) BR9403030A (cs)
CA (1) CA2131350C (cs)
CO (1) CO4290295A1 (cs)
CZ (1) CZ288832B6 (cs)
DE (2) DE4329794C2 (cs)
DK (1) DK0642788T3 (cs)
EC (1) ECSP941148A (cs)
ES (1) ES2119034T3 (cs)
FI (1) FI113336B (cs)
HK (1) HK1010447A1 (cs)
HU (1) HU215955B (cs)
IL (1) IL109800A (cs)
LT (1) LT3664B (cs)
MY (1) MY111754A (cs)
PE (1) PE10195A1 (cs)
PL (1) PL177315B1 (cs)
RU (1) RU2138253C1 (cs)
SI (1) SI0642788T1 (cs)
UA (1) UA26455C2 (cs)
UY (1) UY23804A1 (cs)
ZA (1) ZA946775B (cs)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
HU226595B1 (en) * 1996-03-08 2009-04-28 Nycomed Danmark As Modified release multiple-units dosage composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
DE19712398A1 (de) * 1997-03-25 1998-10-01 Gruenenthal Gmbh Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel
JP3739410B2 (ja) * 1997-07-02 2006-01-25 ユーロ−セルティーク エス．エイ． 安定化された徐放性トラマドール製剤
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
DE29818454U1 (de) * 1998-10-15 1999-01-14 Euroceltique S.A., Luxemburg/Luxembourg Opioid-Analgetikum
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
WO2000040205A2 (en) * 1999-01-05 2000-07-13 Copley Pharmaceutical Inc. Sustained release formulation with reduced moisture sensitivity
DE19901692C2 (de) * 1999-01-18 2002-06-20 Gruenenthal Gmbh Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes
DE19901686A1 (de) * 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
WO2001015683A1 (de) * 1999-08-31 2001-03-08 Grünenthal GmbH Retardierte darreichungsform enthaltend tramadolsaccharinat
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
SK285128B6 (sk) * 1999-12-28 2006-07-07 Zentiva, A. S. Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
RU2165922C1 (ru) * 2000-07-19 2001-04-27 Государственный научно-исследовательский институт органической химии и технологии Способ получения трамадола
DE60105243T2 (de) * 2000-09-22 2005-11-24 Smb Technology Oral anzuwendende tramadolhaltige Teilchen zur einmal täglichen Verabreichung
MXPA03002769A (es) * 2000-09-29 2003-07-28 Solvay Pharm Bv Formulacion farmaceutica de liberacion sostenida e independiente de la densidad ionica.
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
RU2174836C1 (ru) * 2000-12-15 2001-10-20 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция, обладающая анальгезирующим действием
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
JP4377585B2 (ja) 2001-03-16 2009-12-02 ディーエムアイ バイオサイエンシズ インコーポレイテッド 射精遅延の方法
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20060099249A1 (en) * 2002-02-21 2006-05-11 Pawan Seth Modified release formulations of at least one form of tramadol
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
IL164077A0 (en) * 2002-03-22 2005-12-18 Cilag Ag Sustained release formulation of tramadol
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
DE10224108A1 (de) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CA2513893A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
DE10333835A1 (de) * 2003-07-24 2005-03-10 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
KR20120104199A (ko) * 2003-08-06 2012-09-20 그뤼넨탈 게엠베하 남용 방지 제형
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
AU2006269225B2 (en) * 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
EA014739B1 (ru) 2005-09-09 2011-02-28 Лабофарм Инк. Композиция тразодона для введения один раз в день
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
JP5550101B2 (ja) 2007-02-12 2014-07-16 ヴィリックス ファーマシューティカルズ インコーポレイテッド トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8895066B2 (en) * 2007-10-16 2014-11-25 Paladin Labs Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
CN102014877B (zh) 2008-01-25 2017-06-06 格吕伦塔尔有限公司 药物剂型
ES2599031T3 (es) * 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
WO2010069050A1 (en) 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
HUE042987T2 (hu) 2009-07-22 2019-07-29 Gruenenthal Gmbh Visszaéléssel szemben ellenálló adagolási forma oxidációra érzékeny opioidok számára
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
CN102821757B (zh) * 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CA2801620A1 (en) 2010-07-06 2012-01-12 Gruenenthal Gmbh Novel gastro-retentive dosage forms comprising a gaba analog and an opioid
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
JP5925779B2 (ja) 2010-09-02 2016-05-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 無機塩を含む不正使用抵抗性剤形
US20120202838A1 (en) * 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
DK2736495T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
JPS5492631A (en) * 1977-12-27 1979-07-23 Kowa Co Analgestic
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH04217925A (ja) * 1990-03-27 1992-08-07 Nippon Saafuakutanto Kogyo Kk 新規な解熱消炎鎮痛剤組成物
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE4315525B4 (de) * 1993-05-10 2010-04-15 Euro-Celtique S.A. Pharmazeutische Zusammensetzung

Also Published As

Publication number Publication date
FI113336B (fi) 2004-04-15
IL109800A (en) 2000-06-01
CZ214094A3 (en) 1995-03-15
EP0642788A3 (cs) 1995-04-12
HU9402478D0 (en) 1994-10-28
ECSP941148A (es) 1995-01-16
IL109800A0 (en) 1994-08-26
CN1106656A (zh) 1995-08-16
PL177315B1 (pl) 1999-10-29
DE59406075D1 (de) 1998-07-02
CO4290295A1 (es) 1996-04-17
EP0642788B1 (de) 1998-05-27
CN1092956C (zh) 2002-10-23
JP3954117B2 (ja) 2007-08-08
KR950007841A (ko) 1995-04-15
FI944035L (fi) 1995-03-04
FI944035A0 (fi) 1994-09-02
LTIP2033A (en) 1995-03-27
PL304860A1 (en) 1995-03-06
BR9403030A (pt) 1995-05-02
SI0642788T1 (en) 1998-08-31
HU215955B (hu) 1999-03-29
DK0642788T3 (da) 1999-01-18
DE4329794C2 (de) 1997-09-18
MY111754A (en) 2000-12-30
CZ288832B6 (cs) 2001-09-12
RU2138253C1 (ru) 1999-09-27
ZA946775B (en) 1995-04-21
HUT70438A (en) 1995-10-30
DE4329794A1 (de) 1995-03-09
AU671384B2 (en) 1996-08-22
CA2131350C (en) 2005-08-16
AU7280394A (en) 1995-03-16
UA26455C2 (uk) 1999-08-30
ATE166575T1 (de) 1998-06-15
EP0642788A2 (de) 1995-03-15
US5601842A (en) 1997-02-11
LT3664B (en) 1996-01-25
KR100325494B1 (ko) 2002-06-22
PE10195A1 (es) 1995-03-31
JPH07196482A (ja) 1995-08-01
RU94032150A (ru) 1996-11-10
UY23804A1 (es) 1994-07-22
ES2119034T3 (es) 1998-10-01
CA2131350A1 (en) 1995-03-04

Similar Documents

Publication Publication Date Title
HK1010447A1 (en) Tramadol salt containing medicaments with sustained release of the active ingredient
HK1010447B (en) Tramadol salt containing medicaments with sustained release of the active ingredient
FI83037B (fi) Foerfarande foer framstaellning av en naproxen och natrium naproxentablett med styrd utloesning.
EP0797991B1 (en) Extended release formulation containing venlafaxine
US5599577A (en) Simethicone containing pharmaceutical compositions
US20110177168A1 (en) Composition
AU2002322964B2 (en) Dosage forms having prolonged active ingredient release
EP3878445A2 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
NZ200244A (en) Gallopamil or verapamil as calcium-antagonistic active compounds in sustained release pharmaceutical compositions
WO2004078111A2 (en) Extended release minocycline compositions and processes for their preparation
WO2004096186A1 (en) Extended release venlafaxine tablet formulation
AU2003215671A1 (en) Sustained release formulation of tramadol
WO2003082261A1 (en) Extended release venlafaxine formulations
AU2006291422B2 (en) 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation
EP1331003B1 (en) Extended release formulation containing venlafaxine
CA2343270C (en) Methazolamide compositions and method of use
WO2008038106A1 (en) Venlafaxine extended release formulations
AU2003285739B2 (en) Extended release venlafaxine tablet formulation
JP2006509789A (ja) 不安症治療法及び治療薬
HK1056686B (en) Extended release formulation containing venlafaxine
HK1068539B (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
HK1068539A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU6544200A (en) Extended release formulation
HK1070821B (en) Extended release venlafaxine tablet formulation

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20140823